Q2 Earnings Forecast for VRDN Issued By B. Riley

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will earn ($1.14) per share for the quarter. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

Several other analysts also recently commented on the stock. Royal Bank of Canada raised their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 17th. Wells Fargo & Company restated an "equal weight" rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen assumed coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a "buy" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Remove Ads

Viridian Therapeutics Trading Up 0.4 %

Shares of NASDAQ:VRDN traded up $0.06 during midday trading on Tuesday, reaching $15.94. The company's stock had a trading volume of 1,008,783 shares, compared to its average volume of 1,180,883. Viridian Therapeutics has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a 50 day moving average price of $17.86 and a two-hundred day moving average price of $19.64. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.70 and a beta of 1.05.

Institutional Trading of Viridian Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC lifted its stake in Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock valued at $410,000 after acquiring an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL raised its holdings in shares of Viridian Therapeutics by 3.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after purchasing an additional 1,106 shares during the last quarter. R Squared Ltd bought a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $26,000. Summit Investment Advisors Inc. lifted its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after purchasing an additional 1,516 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after purchasing an additional 1,519 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.